» Articles » PMID: 38466661

Development of a Series of Pyrrolopyridone MAT2A Inhibitors

Abstract

The optimization of an allosteric fragment, discovered by differential scanning fluorimetry, to an in vivo MAT2a tool inhibitor is discussed. The structure-based drug discovery approach, aided by relative binding free energy calculations, resulted in AZ'9567 (), a potent inhibitor in vitro with excellent preclinical pharmacokinetic properties. This tool showed a selective antiproliferative effect on methylthioadenosine phosphorylase (MTAP) KO cells, both in vitro and in vivo, providing further evidence to support the utility of MAT2a inhibitors as potential anticancer therapies for MTAP-deficient tumors.

Citing Articles

SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the -adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in....

Yu Z, Kuang Y, Xue L, Ma X, Li T, Yuan L MedComm (2020). 2024; 5(10):e705.

PMID: 39309689 PMC: 11413503. DOI: 10.1002/mco2.705.


Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.

Fogal V, Michopoulos F, Jarnuczak A, Hamza G, Harlfinger S, Davey P Arch Toxicol. 2024; 98(8):2589-2603.

PMID: 38755480 PMC: 11272821. DOI: 10.1007/s00204-024-03771-w.